142 related articles for article (PubMed ID: 18636751)
1. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.
Liu M; Choi S; Cuny GD; Ding K; Dobson BC; Glicksman MA; Auerbach K; Stein RL
Biochemistry; 2008 Aug; 47(32):8367-77. PubMed ID: 18636751
[TBL] [Abstract][Full Text] [Related]
2. Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect.
Liu M; Girma E; Glicksman MA; Stein RL
Biochemistry; 2010 Jun; 49(23):4921-9. PubMed ID: 20491486
[TBL] [Abstract][Full Text] [Related]
3. Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells.
Jämsä A; Bäckström A; Gustafsson E; Dehvari N; Hiller G; Cowburn RF; Vasänge M
Biochem Biophys Res Commun; 2006 Jun; 345(1):324-31. PubMed ID: 16678793
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.
Corbel C; Zhang B; Le Parc A; Baratte B; Colas P; Couturier C; Kosik KS; Landrieu I; Le Tilly V; Bach S
Chem Biol; 2015 Apr; 22(4):472-482. PubMed ID: 25865311
[TBL] [Abstract][Full Text] [Related]
5. No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.
Peterson DW; Ando DM; Taketa DA; Zhou H; Dahlquist FW; Lew J
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2884-9. PubMed ID: 20133653
[TBL] [Abstract][Full Text] [Related]
6. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.
Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS
Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765
[TBL] [Abstract][Full Text] [Related]
7. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
8. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
[TBL] [Abstract][Full Text] [Related]
9. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
10. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.
Hashiguchi M; Saito T; Hisanaga S; Hashiguchi T
J Biol Chem; 2002 Nov; 277(46):44525-30. PubMed ID: 12226093
[TBL] [Abstract][Full Text] [Related]
11. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex.
Hamdane M; Sambo AV; Delobel P; Bégard S; Violleau A; Delacourte A; Bertrand P; Benavides J; Buée L
J Biol Chem; 2003 Sep; 278(36):34026-34. PubMed ID: 12826674
[TBL] [Abstract][Full Text] [Related]
12. Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells.
Shelton SB; Krishnamurthy P; Johnson GV
J Neurosci Res; 2004 Apr; 76(1):110-20. PubMed ID: 15048935
[TBL] [Abstract][Full Text] [Related]
13. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.
Zhou J; Wang H; Feng Y; Chen J
Life Sci; 2010 Mar; 86(13-14):532-7. PubMed ID: 20153752
[TBL] [Abstract][Full Text] [Related]
15. Development of an assay to screen for inhibitors of tau phosphorylation by cdk5.
Ahn JS; Musacchio A; Mapelli M; Ni J; Scinto L; Stein R; Kosik KS; Yeh LA
J Biomol Screen; 2004 Mar; 9(2):122-31. PubMed ID: 15006135
[TBL] [Abstract][Full Text] [Related]
16. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
17. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.
Han P; Dou F; Li F; Zhang X; Zhang YW; Zheng H; Lipton SA; Xu H; Liao FF
J Neurosci; 2005 Dec; 25(50):11542-52. PubMed ID: 16354912
[TBL] [Abstract][Full Text] [Related]
18. p25/CDK5 is partially involved in neuronal injury induced by radiofrequency electromagnetic field exposure.
Zhang Y; She F; Li L; Chen C; Xu S; Luo X; Li M; He M; Yu Z
Int J Radiat Biol; 2013 Nov; 89(11):976-84. PubMed ID: 23786497
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.
Clare PM; Poorman RA; Kelley LC; Watenpaugh KD; Bannow CA; Leach KL
J Biol Chem; 2001 Dec; 276(51):48292-9. PubMed ID: 11604388
[TBL] [Abstract][Full Text] [Related]
20. PHF-like tau phosphorylation in mammalian hibernation is not associated with p25-formation.
Stieler JT; Bullmann T; Kohl F; Barnes BM; Arendt T
J Neural Transm (Vienna); 2009 Mar; 116(3):345-50. PubMed ID: 19184336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
